Drug pricing white paper allays pharma patent fears, but innovators should remain vigilant 23 Feb 18
A recent report from the US president’s executive office on reducing drug prices makes reassuring reading for innovators concerned about the future of pharmaceutical patents under the Trump administration. In contrast to comments previously made by the president and his new health secretary Alex Azar, the paper robustly defends innovators’ IP rights, while recommending regulatory and insurance reforms, as well as a clamp down on foreign “free-riding”, to lower medical costs.
Want to read more?
Register to access two of our subscriber-only articles per month
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts
What our customers are saying
Well-written, in-depth coverage that is not found on this side of the ‘pond’. Thank you for that.
Frederic M Wilf
Technology, intellectual property and business lawyer
Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email